Evidence map›Paper›PMID 29587780›Full record

ArticleVirology journal2018

Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).

Nor Azila Muhammad Azami, Meng Ling Moi, Yasushi Ami, Yuriko Suzaki, Chang-Kweng Lim, Satoshi Taniguchi, Masayuki Saijo, Tomohiko Takasaki, Ichiro Kurane

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nor Azila Muhammad AzamiDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
Meng Ling MoiDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
Yasushi AmiDivision of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo, Japan.
Yuriko SuzakiDivision of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo, Japan.
Chang-Kweng LimDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
Satoshi TaniguchiDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
Masayuki SaijoDepartment of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
Tomohiko TakasakiKanagawa Prefectural Institute of Public Health, Kanagawa, Japan.
Ichiro KuraneNational Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan. kurane@nih.go.jp.
National Institute of Infectious Diseases · JPKanagawa Prefectural Institute of Public Health · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA vaccine against all four dengue virus (DENV) serotypes includes the formulation of one genotype of each serotype. Although genetic similarities among genotypes within a serotype are higher as compared to those among serotypes, differences in the immunogenicity of the included genotypes would be a critical issue in maximizing successful dengue vaccine development. Thus, we determined the neutralizing antibody responses against three genotypes of dengue virus serotype 2 (DENV-2), namely Cosmopolitan, Asian I, and Asian/American, after primary and secondary inoculation with DENV-2 in a dengue animal model, the common marmoset (Callithrix jacchus).

methodsA total of fifty-four plasma samples were obtained from thirty-four marmosets that were inoculated with clinically-isolated DENV strains or DENV candidate vaccines, were used in this study. Plasma samples were obtained from marmosets after primary inoculation with DENV-2 infection, secondary inoculation with homologous or heterologous genotypes, and tertiary inoculation with heterologous DENV. Neutralizing antibody titers against DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes) and DENV-1 were determined using a conventional plaque reduction neutralization assay.

resultsIn marmosets that were inoculated with the Cosmopolitan genotype in primary infection, neutralizing antibody neutralized 3 genotypes, and the titers to Asian I genotype were significantly higher than those to homologous Cosmopolitan genotype. After secondary DENV-2 infection with heterologous genotype (Asian I in primary and Asian/American in secondary), neutralizing antibody titers to Asian/American genotype was significantly higher than those against Cosmopolitan and Asian I genotypes. Following tertiary infection with DENV-1 following DENV-2 Asian I and Cosmopolitan genotypes, neutralizing antibody titers to Asian/American were also significantly higher than those against Cosmopolitan and Asian I genotypes.

conclusionThe present study demonstrated that different levels of neutralizing antibodies were induced against variable DENV-2 genotypes after primary, secondary and tertiary infections, and that neutralizing antibody titers to some heterologous genotypes were higher than those to homologous genotypes within a serotype. The results indicate that heterogeneity and homogeneity of infecting genotypes influence the levels and cross-reactivity of neutralizing antibodies induced in following infections. The results also suggest that certain genotypes may possess advantage in terms of breakthrough infections against vaccination.

Indexed as

GenotypeAnimalsAntibodies, NeutralizingAntibodies, ViralAntibody SpecificityCallithrixCoinfectionCross ReactionsDengueDengue VaccinesDengue VirusDisease Models, AnimalNeutralization TestsSerogroupAntibodies, NeutralizingAntibodies, ViralDengue VaccinesAnimal modelAntibody responseDengueGenotype

Identifiers

PMID29587780
PMCPMC5870686
OpenAlexW2794526618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.